AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 81 min read$BCDA

Altman Peter purchased $5K of BCDA

Altman Peter (President and CEO) purchased 5,400 shares of BioCardia, Inc. (BCDA) at $0.96 on 2026-07-08.

Original reporting
SEC EDGAR · Altman Peter
Published Jul 8, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BCDA
Bullish
low confidence
Mentioned
$BCDA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BCDABullishLow
01

Why it matters

A CEO open-market purchase is a positive sentiment datapoint, but the text lacks any fundamental update (earnings, trial results, financing, or regulatory action).

02

Market read

Traders may note the insider buy as a small bullish sentiment input, but it is unlikely to drive a major repricing without additional catalysts.

03

What to watch

The filing notes no 10b5-1 plan and provides no rationale; without follow-on disclosures (guidance, trial updates, financing), the signal may be weak.

Relevance 4/10Novelty 5/10Timing: filed on 2026-07-08 (same day as reported purchase)

Background

The article is a SEC Form 4 insider transaction disclosure for BioCardia, Inc.

Company-level read

Ticker impact

$BCDABullishLow confidence
Context

BioCardia CEO Altman Peter filed a Form 4 for an open-market purchase of 5,400 shares at $0.9645 on 2026-07-08.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

Form 4 insider buys can be read as confidence signals, but the article provides no accompanying operational or financial catalyst, and the transaction value is modest.

Market effects

Sector

No sector-wide implications; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider open-market buys can be routine liquidity or compensation-related and may not reflect a new view on near-term prospects.

Key entities

  • issuer
    BioCardia, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Altman Peter

    President and CEO who purchased 5,400 shares on 2026-07-08.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BCDA insider trading history →

Related articles

OCT 19
$BCDAMedAI 8/10

BioCardia Advances Helix Catheter Toward FDA Marketing Clearance

BioCardia (BCDA) submitted a revised De Novo pre-submission package to the FDA for its Helix catheter, following feedback. The FDA accepted the submission and expects review, feedback, and a meeting in Q4 2026. The catheter is designed for delivering therapeutic agents to heart muscle and has clinical safety data from 15 trials. FDA clearance could expand partnership opportunities for BCDA.

rttnews.com2 min
OCT 19
$BCDAHighAI 8/10

BioCardia: FDA Accepts De Novo Pre-Submission for Helix Catheter; Substantive Review, Meeting Expected This Quarter

BioCardia's FDA pre-submission for Helix catheter was accepted, with substantive review and a meeting expected this quarter. The FDA raised no concerns about safety or performance. The company has clinical data from 15 trials supporting potential clearance, which could expand partnerships. According to the company, marketing clearance could enhance opportunities with cardiac biologics developers.

tradingview.com1 min
OCT 19
$BCDAMedAI 8/10

FDA accepts BioCardia pre-submission for Helix catheter

BioCardia Inc. (BCDA) announced the FDA accepted its pre-submission for the Helix catheter, a device for heart agent delivery. The FDA indicated two pathways for clearance and raised no safety concerns. BioCardia expects substantive review and feedback this quarter. The Helix catheter is supported by clinical data from 15 trials with nearly 500 patients.

investing.com2 min
OCT 19
$BCDAHighAI 8/10

BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for HelixTM Catheter Marketing Clearance FDA Substantive Review and Meeting Expected…

BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix TM Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter October 19, 2026, Sunnyvale, Calif. BioCardia, Inc. [NASDAQ: BCDA] , a global leader in cellular an

SEC EDGAR 8-K2 min